[go: up one dir, main page]

WO2007090846A1 - Agents hémostatiques - Google Patents

Agents hémostatiques Download PDF

Info

Publication number
WO2007090846A1
WO2007090846A1 PCT/EP2007/051167 EP2007051167W WO2007090846A1 WO 2007090846 A1 WO2007090846 A1 WO 2007090846A1 EP 2007051167 W EP2007051167 W EP 2007051167W WO 2007090846 A1 WO2007090846 A1 WO 2007090846A1
Authority
WO
WIPO (PCT)
Prior art keywords
minerals
composition according
wound
natural
haemostasis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/051167
Other languages
German (de)
English (en)
Other versions
WO2007090846B1 (fr
Inventor
Joachim Schomburg
Christian Schultz
Wolf-Dieter Juelich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DURTEC GmbH
Original Assignee
DURTEC GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DURTEC GmbH filed Critical DURTEC GmbH
Priority to EP07712163A priority Critical patent/EP1986704A1/fr
Publication of WO2007090846A1 publication Critical patent/WO2007090846A1/fr
Publication of WO2007090846B1 publication Critical patent/WO2007090846B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • the invention relates to the use of naturally occurring zeolites as agents for hemostasis and / or for the production of cosmetic or medical formulations.
  • a) protein denaturation e.g. B. by metal salts
  • b) microporous biopolymers or biopolymers with a large inner surface area These absorb water, resulting in a concentration of red blood cells and coagulation factors.
  • Polysacharides which consist of poly-N-acetyl-glucosamines or chitosan have proved to be particularly advantageous. These are z. B. in the skeleton of insects, but also in algae.
  • Biopolymers such as gelatin, fibrin sponges or oxidized cellulose have a large internal surface area. Due to the absorption on this large area, a concentration of coagulation factors occurs.
  • the alumo silicate synthesis products with microporous structure represent the closer prior art.
  • the synthesis products used hitherto for hemostasis are alkali and Erdaluminiumsilicate different composition.
  • a synthesis product was developed by the company Z-Medica, US for the immediate treatment of war injuries and emergency care.
  • a strong exothermic reaction deprives the blood of water and bleeding it.
  • the synthesis product is applied directly in granular form to the wound. It is marketed under the name "Quikclot.”
  • a disadvantage of this product has been described that the exothermic reaction (temperatures up to 60 0 C) damage the adjacent tissue occur (Journal of Trauma 54 (2003) 6, 1077-1082).
  • a clay mineral binder is additionally used for product presentation in order to better control the exothermic effect over different moisture contents and to reduce heat development at the wound.
  • Synthetic lithium aluminosilicates (EP 1 176 991 A1, WO 00/69480 A1) have been developed especially for wound care and are sold under the trade name CERDAC.
  • CERDAC Synthetic lithium aluminosilicates
  • the object of the invention was to eliminate the disadvantages mentioned in the prior art and to provide new possibilities for haemostasis.
  • natural minerals with a content of> 70% zeolite preferably with fractions of clinoptilolite, chabazite and mordenite, fractionated after drying and pre-crushing.
  • the fraction is used with grain band 0.2 - 1.5 mm.
  • the gentle dehydration is carried out at temperatures below 200 0 C by treatment in selected Termperaturintervallen.
  • a mineral fine granules with strong electrostatic fields in the crystal lattice is obtained, which can even stop heavy bleeding within 1 minute.
  • the high capillary force is also for use for wound care, especially for the treatment of difficult-to-heal and already chronic wounds, of particular importance. Particularly indicated is the use in wounds with an exudation, ie an escape of blood components on an inflamed wound. Often, exudation is an indication of infection from an injury.
  • the microporous structure according to the invention makes it possible to absorb wound exudate that is released in excess in the case of "weeping" wounds.At the same time, the uptake of the excess exudate ensures a moist atmosphere over the wound, which promotes wound healing, in particular also for the prevention of late dermatological damage.
  • the agent is also particularly suitable for use in high-risk patients such as diabetics and dialysis patients. It has surprisingly been found that the zeolites prepared according to the invention retain their hemostatic activity even in moist mixtures. As a result, the application is also possible in moist wound treatment.
  • the Naturzeolithfeingranulate can be in a sheath - preferably on a cellulose basis or on a textile basis or a collagen fleece - are, advantageously a fixation in the desired position by quilting and sewing can be done.
  • Selected natural zeolites can be prepared according to the invention so that they can now be provided on a cost-effective direct route as hemostatic agents and wound care agents.
  • the products prepared according to Example 1 have 25 - 50% microporous space (based on the total volume) and average nanopore diameter in the range 0.3 - 0.5 nm.
  • Nanopore size and Feingranulat allow maximum Blutadsorption and rapid penetration of Adsorberfeingranulates.
  • the capillary force effect is 5- to 10-fold higher than in the comparatively studied commercial preparation CERDAC.
  • Rats were anesthetized for this purpose. After opening the abdominal cavity, the scalpel was used to make a section about 1 cm long. The bleeding was filmed. The time to hemostasis was measured.
  • hemostasis is achieved within 1 minute (control up to 8 minutes). It forms a scab-like encrustation that protects the wound.
  • the pigs were anesthetized. With the scalpel 7 - 10 cm long cuts were made. The time to hemostasis following the application of pads with 10 g fine granule filling was measured.
  • haemostasis of the pig liver wound was achieved in response to subjects after 120 to 600 seconds.
  • the Naturstofffeingranulat was tested in the liver section model according to Example 3.
  • the granules were not scattered but wrapped in a nonwoven web of native resorbable collagen fibers made from pig skin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne l'utilisation de zéolithes d'origine naturelle en tant qu'agents hémostatiques et/ou pour produire des cosmétiques (par ex. du dentifrice) ou des formulations médicales. Les agents selon l'invention sont caractérisés en ce qu'ils contiennent, en tant que principe actif, des granulés fins de zéolithes d'origine naturelle pouvant être obtenus à partir de substances minérales naturelles présentant une teneur en zéolithe = 70 %. De préférence, les minéraux utilisés sont la clinoptilolithe et/ou la chabazite et/ou la mordénite.
PCT/EP2007/051167 2006-02-09 2007-02-07 Agents hémostatiques Ceased WO2007090846A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07712163A EP1986704A1 (fr) 2006-02-09 2007-02-07 Agents hémostatiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006006905A DE102006006905A1 (de) 2006-02-09 2006-02-09 Mittel zur Blutstillung
DE102006006905.6 2006-02-09

Publications (2)

Publication Number Publication Date
WO2007090846A1 true WO2007090846A1 (fr) 2007-08-16
WO2007090846B1 WO2007090846B1 (fr) 2007-10-18

Family

ID=38157797

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/051167 Ceased WO2007090846A1 (fr) 2006-02-09 2007-02-07 Agents hémostatiques

Country Status (3)

Country Link
EP (1) EP1986704A1 (fr)
DE (1) DE102006006905A1 (fr)
WO (1) WO2007090846A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116350832A (zh) * 2023-04-11 2023-06-30 上海市第十人民医院 一种基于沸石的复合止血剂及其制备方法
WO2025232973A1 (fr) * 2024-05-08 2025-11-13 Froximun Ag Mélange minéral contenant de la clinoptilolite ou clinoptilolite destiné à être utilisé en tant que pansement pour plaie minéral

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09124451A (ja) * 1995-11-01 1997-05-13 Sangi Co Ltd 歯磨組成物
WO2002030479A1 (fr) * 2000-10-13 2002-04-18 On Site Gas Systems, Inc. Bandage utilisant des tamis moleculaires
US20050058721A1 (en) * 2003-09-12 2005-03-17 Hursey Francis X. Partially hydrated hemostatic agent
EP1690553A1 (fr) * 2005-02-09 2006-08-16 Jeffrey L. Horn Dispositifs et méthodes pour l'administration de tamis moléculaires pour la formation de caillots sanguins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09124451A (ja) * 1995-11-01 1997-05-13 Sangi Co Ltd 歯磨組成物
WO2002030479A1 (fr) * 2000-10-13 2002-04-18 On Site Gas Systems, Inc. Bandage utilisant des tamis moleculaires
US20050058721A1 (en) * 2003-09-12 2005-03-17 Hursey Francis X. Partially hydrated hemostatic agent
EP1690553A1 (fr) * 2005-02-09 2006-08-16 Jeffrey L. Horn Dispositifs et méthodes pour l'administration de tamis moléculaires pour la formation de caillots sanguins

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116350832A (zh) * 2023-04-11 2023-06-30 上海市第十人民医院 一种基于沸石的复合止血剂及其制备方法
WO2025232973A1 (fr) * 2024-05-08 2025-11-13 Froximun Ag Mélange minéral contenant de la clinoptilolite ou clinoptilolite destiné à être utilisé en tant que pansement pour plaie minéral

Also Published As

Publication number Publication date
EP1986704A1 (fr) 2008-11-05
WO2007090846B1 (fr) 2007-10-18
DE102006006905A1 (de) 2007-08-23

Similar Documents

Publication Publication Date Title
DE60008790T2 (de) Medizinische verbände enthaltend gelartigen honig
DE68918538T2 (de) Wundenausfüllmittel.
DE68914110T2 (de) Hämostastische Collagenpastenmaterialzusammensetzung.
DE60203783T2 (de) Medizinischer verband mit einer antimikrobiellen silberverbindung
EP2468307B1 (fr) Matrices de collagène stables en dégradation et biocompatibles
DE69032125T2 (de) Gelwundverbandszusammensetzungen und verfahren zu deren gebrauch
DE69928690T2 (de) Zusammensetzung und Verfahren zur Bindung von Hautirritierenden Mitteln.
DE602004002717T2 (de) Blattförmige Wundauflage aus mikrobieller Zellulose, enthaltend PHMB, für chronische Wunden
DE2148083C2 (de) Hämostatischer Wundverband aus Fasern aus Kollagen oder einem ionisierbaren partiellen Kollagensalz und Verfahren zu seiner Herstellung
DE2918098A1 (de) Haemostatisches mittel, verfahren zu seiner herstellung und seine verwendung zur kontrolle doer stillung einer blutung
DE102005060461A1 (de) Medizinische Zusammensetzung
DE4206857A1 (de) Polymerzusammensetzung, absorptionsmaterialzusammensetzung, deren herstellung und verwendung
DE3017221C2 (fr)
DE212012000057U1 (de) Antimikrobielles Gemisch und eine antimikrobiell wirkende Abdeckung zur Unterstützung der Wundheilung
WO2007074327A1 (fr) Substance hémostatique
EP2104519B1 (fr) Composition de gel filmogène pour soigner la peau ou une blessure
DE102005035879A1 (de) Hydrogel
DE3686702T2 (de) Biologisch aktive topische kollagentraegermatrix: kosmetische und pharmazeutische verwendung und verfahren zu deren herstellung.
EP2098255B1 (fr) Procédé de fabrication de matériau collagène
EP1986704A1 (fr) Agents hémostatiques
EP0908169B1 (fr) Composition pour pansements liquides
DE69105077T2 (de) Verwendung von Polysacchariden in Zubereitungen zur Wundbehandlung.
DE202023100113U1 (de) Dreidimensional vernetztes Hydrogel
DE60204614T2 (de) Narbenbildung fördernder hydrokolloidaler Wundverband, welcher Hyaluronsäure und Chondroitinsulfat enthält
DE102013111322A1 (de) Verfahren zur Herstellung von Hydrokolloid-Schwämmen

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007712163

Country of ref document: EP